Lorlatinib/lorlatinib’s launch time and market response

Lorlatinib/ Lorlatinib ( Lorlatinib) was developed by a pharmaceutical company and was approved by the FDA in the United States in 2018. It is used to treat ALK-positive advanced non-small cell lung cancer patients who have previously received first- or second-generation ALK inhibitors. This approval is based on the results of multiple international multi-center clinical studies, showing that lorlatinib has significant advantages in central nervous system metastasis control and systemic tumor suppression, making it quickly become an important treatment option for ALK-positive NSCLC.

In the US and European markets, the launch of lorlatinib has received widespread attention from patient groups and clinicians. As a third-generation ALK inhibitor, it not only has better systemic efficacy than earlier drugs, but can also effectively cross the blood-brain barrier and show unique efficacy in patients with brain metastases. This is of particular concern to doctors because patients with ALK-positive NSCLC have a high risk of brain metastasis, and traditional ALK inhibitors have limited efficacy in the brain.

In terms of market response, lorlatinib is recognized for its significant efficacy, convenient oral administration, and long-term maintenance treatment. However, high drug prices have also raised concerns, especially in areas with limited health insurance coverage. In the domestic market, lorlatinib has been approved, but there are differences in its inclusion in medical insurance and pricing policies. Some patients purchase medicines through specific channels to obtain treatment opportunities, and medical institutions are also formulating standardized medication plans based on clinical guidelines.

In general, since its launch, lorlatinib has won market and clinical recognition for its unique targeting mechanism, efficacy in patients with drug resistance and brain metastasis, and high safety. With further clinical research and the development of new indications, lorlatinib's position in the treatment of ALK-positive NSCLC is expected to be further consolidated, while also providing more treatment options for drug-resistant patients.

Reference materials：https://www.lorbrena.com/